MX 0612
Alternative Names: MX-0612Latest Information Update: 26 Nov 2024
Price :
$50 *
At a glance
- Originator MESOX
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 25 Nov 2024 Preclinical trials in Obesity in United Kingdom (unspecified route), before November 2024 (MESOX pipeline, November 2024)